ZBIO

Zenas is a clinical-stage immunology play whose entire value rests on obexelimab, and the recent clinical read-outs are genuinely de-risking. The January 2026 Phase 3 in IgG4-RD hit its primary endpoint with a 56% reduction in flare risk (HR 0.44, p=0.0005) and swept all four key secondary endpoints, with a BLA submission planned for Q2 2026 and an EMA MAA in 2H 2026. The Phase 2 MoonStone trial in RMS showed a 95% relative reduction in new Gd-enhancing lesions (p=0.0009) sustained through 24 weeks, and a Phase 2 SLE read-out (SunStone) is due Q4 2026. For a name whose $10.0M FY2025 revenue and 156x P/S are meaningless, this pipeline optionality — not the income statement — is the asset, and a pending first BLA is the closest a clinical biotech gets to a hard catalyst.

The problem is the balance sheet cannot comfortably reach the finish line. Cash fell 65% to $111M while operating cash burn ran -$172M in FY2025, implying well under a year of runway before commercialization spend even ramps for a potential IgG4-RD launch. The -$378M net loss (far wider than the -$172M cash burn) reflects large non-cash charges tied to R&D and the October 2025 InnoCare licensing deal (orelabrutinib, ZB021, ZB022), but the cash trajectory is the binding constraint. Share count already rose 37% YoY, and a further sizeable equity raise looks near-certain — a dilution overhang that caps near-term upside even on good news.